Virtual platform for intellectual property sharing aims to speed development of drug treatments

"The World Intellectual Property Organization (WIPO) launched a consortium on Wednesday that would allow the public and private sector to share intellectual property to promote the development of new drugs to treat diseases such as malaria," Reuters reports (10/26). "Under the agreement between [WIPO], ... [pharmaceutical] companies and the non-profit BIO Ventures for Global Health (BVGH), public and private sector organizations will share valuable intellectual property (IP) and expertise with the global health research community on WIPO Re:Search, a virtual platform," the U.N. News Centre writes (10/26).

"The cooperation is aimed at the development of new drugs and vaccines for around 20 diseases, including neglected tropical diseases, malaria and tuberculosis, and will involve major drugmakers including Novartis, AstraZeneca, GlaxoSmithKline, Pfizer, Merck and Sanofi," according to Agence France-Presse, which adds, "Under the scheme, the intellectual property licenses on these drugs would be available free of charge for the world's poorest countries, said Francis Gurry, who heads [WIPO]" (10/26). "Some of the mechanics of patent sharing, data protection and other details remain to be worked out," the Associated Press notes (10/26).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Do GLP-1 drugs shrink your muscles? New study explains the risks and what to do